Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)
This trial is active, not recruiting.
|Condition||pain associated with fibromyalgia|
|Start date||February 2013|
|End date||June 2017|
|Trial size||600 participants|
|Trial identifier||NCT01773993, A0081282|
To collect the efficacy and safety information of Pregabalin on Fibromyalgia patients related to their appropriate use in daily practice.
Number of Participants with Change from Baseline in Clinical Global Impression of Clinical Condition (CGI-C) at Month X
time frame: 12 months
Male or female participants of any age.
Inclusion Criteria: - Clinical diagnosis of Fibromyalgia - Pregabalin naive patient Exclusion Criteria: - Clinical diagnosis of neuropathic pain
|Official title||Special Investigation Of Pregabalin For Fibromyalgia|
|Description||All the patients whom an investigator prescribes the first pregabalin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.|
Call for more information